daraxonrasib

Phase 3Small molecule

daraxonrasib is one of 161 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Pancreatic CancerRecruiting

Solid TumorRecruiting

Non-Small Cell Lung Cancer (NSCLC)Recruiting

NSCLC (non-Small Cell Lung Cancer)Recruiting

Pancreatic Ductal AdenocarcinomaPhase 3

Active, not recruiting

Pancreatic AdenocarcinomaPhase 3

Active, not recruiting

Pancreatic CancerPhase 3

Recruiting

Solid TumorPreclinical

Recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 1

Recruiting

NSCLC (non-Small Cell Lung Cancer)Phase 3

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

daraxonrasib

Revolution Medicines

Phase 3

2 2

Gemzar

GGynecologic Oncology Group

Medrol

1 4

Byetta

AstraZeneca

Preclinical

1 5

MS Contin

Merck & Co.

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

Active Comparator

Moderna

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT07349537

Q1 2029

Phase 3Recruiting

Pancreatic Cancer

NCT07491445

Q2 2029

PreclinicalRecruiting

Solid Tumor

NCT07397338

Phase 1/2Recruiting

KRAS G12C Mutant Solid Tumors

NCT06128551

Q3 2030

Phase 3Recruiting

Pancreatic Cancer

NCT07252232

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07252232·500 enrolled

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07491445·900 enrolled

Metastatic Solid Tumors1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

KRAS G12C Mutant Solid Tumors1 trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1/2·NCT06128551·534 enrolled

PDAC1 trial

Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib

Available· Revolution Medicines logo

Revolution Medicines··NCT07573215

Non-small Cell Lung Cancer (NSCLC)1 trial

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1·NCT07349537·574 enrolled

2 more indications

NSCLC (Non-small Cell Lung Cancer)1 trial

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT06881784·590 enrolled

Solid Tumor1 trial

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT07397338·370 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for daraxonrasib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — daraxonrasib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for daraxonrasib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revolution Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Revolution Medicines

daraxonrasib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q2 2029

Q3 2030

Trials by Indication[1]

Pancreatic Cancer2 trials

Metastatic Solid Tumors1 trial

KRAS G12C Mutant Solid Tumors1 trial

PDAC1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

NSCLC (Non-small Cell Lung Cancer)1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News